Skip to main content
SpringerLink
Log in
Book cover

Blaustein’s Pathology of the Female Genital Tract pp 394–452Cite as

Endometrial Carcinoma

  • Reference work entry

  • 5196 Accesses

Abstract

Endometrial carcinoma is the most common invasive neoplasm of the female genital tract and the fourth most frequently diagnosed cancer in women in the USA. In 2008, it is estimated there will have been 40,100 new cases and 7,470 deaths resulting from this neoplasm. These figures represent an estimated 6% of the new cancer cases and 3% of the cancer deaths in women [377]. Worldwide, approximately 150,000 cases are diagnosed each year, making endometrial carcinoma the fifth most common cancer in women [304, 305]. The incidence of endometrial cancer varies widely throughout the world. The highest rates occur in North America and Europe, whereas rates in developing countries and Japan are four to five times lower. The incidence is also about twice as high in whites compared to blacks. However, the proportion of endometrial cancer related deaths is higher in blacks due to a relative increase in the incidence of high-risk endometrial carcinoma in the black population. The reason for this is not well understood but access to and quality of health care as well as genetics are considered possible factors [17].

This is a preview of subscription content, log in via an institution.

References

  1. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development (1987) Combination oral contraceptive use and the risk of endometrial cancer. JAMA 257:796–800

    Article  Google Scholar 

  2. Abeler VM, Kjorstad KE (1991) Clear cell carcinoma of the endometrium: a histopathological and clinical study of 97 cases. Gynecol Oncol 40:207–217

    Article  PubMed  CAS  Google Scholar 

  3. Abeler VM, Kjorstad KE (1991) Endometrial adenocarcinoma in Norway. A study of the total population. Cancer 67:3093–3103

    Article  PubMed  CAS  Google Scholar 

  4. Abeler VM, Kjorstad KE (1992) Endometrial adenocarcinoma with squamous cell differentiation. Cancer 69:488–495

    Article  PubMed  CAS  Google Scholar 

  5. Abeler VM, Kjorstad KE (1990) Serous papillary carcinoma of the endometrium: a histopathological study of 22 cases. Gynecol Oncol 39:266–271

    Article  PubMed  CAS  Google Scholar 

  6. Abeler VM, Kjorstad KE, Berle E (1992) Carcinoma of the endometrium in Norway: a histopathological and prognostic survey of a total population. Int J Gynecol Cancer 2:9–22

    Article  PubMed  Google Scholar 

  7. Abeler VM et al (1996) Clear cell carcinoma of the endometrium. Prognosis and metastatic pattern. Cancer 78:1740–1747

    Article  PubMed  CAS  Google Scholar 

  8. Abu-Rustum NR et al (2008) Is there a therapeutic impact to regional lymphadenectomy in the surgical treatment of endometrial carcinoma? Am J Obstet Gynecol 198:457 e1–e5; discussion 457 e5–e6

    Google Scholar 

  9. Acs G, Pasha T, Zhang PJ (2004) WT1 is differentially expressed in serous, endometrioid, clear cell, and mucinous carcinomas of the peritoneum, fallopian tube, ovary, and endometrium. Int J Gynecol Pathol 23:110–118

    Article  PubMed  Google Scholar 

  10. Al Kushi A et al (2002) Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium. Mod Pathol 15:365–371

    Article  PubMed  Google Scholar 

  11. Alberhasky RC, Connelly PJ, Christopherson WM (1982) Carcinoma of the endometrium. IV. Mixed adenosquamous carcinoma. A clinical-pathological study of 68 cases with long-term follow-up. Am J Clin Pathol 77:655–664

    PubMed  CAS  Google Scholar 

  12. Alexander-Sefre F et al (2004) Clinical value of immunohistochemically detected lymphovascular invasion in endometrioid endometrial cancer. Gynecol Oncol 92:653–659

    Article  PubMed  CAS  Google Scholar 

  13. Ali A, Black D, Soslow RA (2007) Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int J Gynecol Pathol 26:115–123

    Article  PubMed  Google Scholar 

  14. Alkushi A et al (2005) Description of a novel system for grading of endometrial carcinoma and comparison with existing grading systems. Am J Surg Pathol 29:295–304

    Article  PubMed  Google Scholar 

  15. Alkushi A et al (2007) Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data. Mod Pathol 20:1156–1165

    Article  PubMed  CAS  Google Scholar 

  16. Alkushi A et al (2004) Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 23:129–137

    Article  PubMed  Google Scholar 

  17. Allard JE, Maxwell GL (2009) Race disparities between black and white women in the incidence, treatment, and prognosis of endometrial cancer. Cancer Control 16:53–56

    PubMed  Google Scholar 

  18. Altrabulsi B et al (2005) Undifferentiated Carcinoma of the Endometrium. Am J Surg Pathol 29:1316–1321

    Article  PubMed  Google Scholar 

  19. Amant F et al (2005) Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer. Gynecol Oncol 98:274–280

    Article  PubMed  Google Scholar 

  20. Amant F et al (2002) PTEN mutations in uterine sarcomas. Gynecol Oncol 85:165–169

    Article  PubMed  CAS  Google Scholar 

  21. Ambros RA, Kurman RJ (1992) Combined assessment of vascular and myometrial invasion as a model to predict prognosis in stage I endometrioid adenocarcinoma of the uterine corpus. Cancer 69:1424–1431

    Article  PubMed  CAS  Google Scholar 

  22. Ambros RA, Kurman RJ (1992) Identification of patients with stage I uterine endometrioid adenocarcinoma at high risk of recurrence by DNA ploidy, myometrial invasion, and vascular invasion. Gynecol Oncol 45:235–239

    Article  PubMed  CAS  Google Scholar 

  23. Ambros RA et al (1995) Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 26:1260–1267

    Article  PubMed  CAS  Google Scholar 

  24. An HJ et al (2004) Molecular characterization of uterine clear cell carcinoma. Mod Pathol 17:530–537

    Article  PubMed  CAS  Google Scholar 

  25. Andersson M, Storm HH, Mouridsen HT (1991) Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst 83:1013–1017

    Article  PubMed  CAS  Google Scholar 

  26. Ansari-Lari MA et al (2004) Distinction of endocervical and endometrial adenocarcinomas: immunohistochemical p16 expression correlated with human papillomavirus (HPV) DNA detection. Am J Surg Pathol 28:160–167

    Article  PubMed  Google Scholar 

  27. Aquino-Parsons C et al (1998) Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol 71:83–86

    Article  PubMed  CAS  Google Scholar 

  28. Arends JW et al (1984) Adenocarcinoma of the endometrium with glassy-cell features – immunohistochemical observations. Histopathology 8:873–879

    Article  PubMed  CAS  Google Scholar 

  29. Arnett-Mansfield RL et al (2001) Relative expression of progesterone receptors A and B in endometrioid cancers of the endometrium. Cancer Res 61:4576–4582

    PubMed  CAS  Google Scholar 

  30. Arrastia CD et al (1997) Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol 65:158–163

    Article  PubMed  CAS  Google Scholar 

  31. Ashton KA et al (2009) Estrogen receptor polymorphisms and the risk of endometrial cancer. BJOG 116:1053–1061

    Article  PubMed  CAS  Google Scholar 

  32. Austin H, Drews C, Partridge EE (1993) A case-control study of endometrial cancer in relation to cigarette smoking, serum estrogen levels, and alcohol use. Am J Obstet Gynecol 169:1086–1091

    PubMed  CAS  Google Scholar 

  33. Ayhan A et al (2004) The long-term survival of women with surgical stage II endometrioid type endometrial cancer. Gynecol Oncol 93:9–13

    Article  PubMed  Google Scholar 

  34. Backe J et al (1997) p53 protein in endometrial cancer is related to proliferative activity and prognosis but not to expression of p21 protein. Int J Gynecol Pathol 16:361–368

    Article  PubMed  CAS  Google Scholar 

  35. Backe J et al (1997) Immunohistochemically detected HER-2/neu-expression and prognosis in endometrial carcinoma. Arch Gynecol Obstet 259:189–195

    Article  PubMed  CAS  Google Scholar 

  36. Barakat RR et al (1994) Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 55:164–168

    Article  PubMed  CAS  Google Scholar 

  37. Barwick KW, LiVolsi VA (1979) Malignant mixed mullerian tumors of the uterus. A clinicopathologic assessment of 34 cases. Am J Surg Pathol 3:125–135

    Article  PubMed  CAS  Google Scholar 

  38. Beckner ME, Mori T, Silverberg SG (1985) Endometrial carcinoma: nontumor factors in prognosis. Int J Gynecol Pathol 4:131–145

    Article  PubMed  CAS  Google Scholar 

  39. Beral V et al (1999) Use of HRT and the subsequent risk of cancer. J Epidemiol Biostat 4:191–210; discussion 210–215

    PubMed  CAS  Google Scholar 

  40. Berchuck A et al (1991) Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 164:15–21

    PubMed  CAS  Google Scholar 

  41. Bitterman P, Chun B, Kurman RJ (1990) The significance of epithelial differentiation in mixed mesodermal tumors of the uterus. A clinicopathologic and immunohistochemical study. Am J Surg Pathol 14:317–328

    Article  PubMed  CAS  Google Scholar 

  42. Boccardo F et al (1992) Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial. Eur J Cancer 28:673–680

    Article  PubMed  CAS  Google Scholar 

  43. Bodner-Adler B et al (2001) Prognostic parameters in carcinosarcomas of the uterus: a clinico-pathologic study. Anticancer Res 21:3069–3074

    PubMed  CAS  Google Scholar 

  44. Bokhman JV (1983) Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15:10–17

    Article  PubMed  CAS  Google Scholar 

  45. Bonatz G et al (1999) Prognostic significance of a novel proliferation marker, anti-repp 86, for endometrial carcinoma: a multivariate study. Hum Pathol 30:949–956

    Article  PubMed  CAS  Google Scholar 

  46. Boronow RC et al (1984) Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol 63:825–832

    PubMed  CAS  Google Scholar 

  47. Borst MP et al (1990) Oncogene alterations in endometrial carcinoma. Gynecol Oncol 38:364–366

    Article  PubMed  CAS  Google Scholar 

  48. Boyd J, Risinger JI (1991) Analysis of oncogene alterations in human endometrial carcinoma: prevalence of ras mutations. Mol Carcinog 4:189–195

    Article  PubMed  CAS  Google Scholar 

  49. Brandenberger AW et al (1999) Oestrogen receptor (ER)-alpha and ER-beta isoforms in normal endometrial and endometriosis-derived stromal cells. Mol Hum Reprod 5:651–655

    Article  PubMed  CAS  Google Scholar 

  50. Brinton LA et al (1992) Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 167:1317–1325

    PubMed  CAS  Google Scholar 

  51. Britton LC et al (1989) Flow cytometric DNA analysis of stage I endometrial carcinoma. Gynecol Oncol 34:317–322

    Article  PubMed  CAS  Google Scholar 

  52. Broaddus RR et al (2006) Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106:87–94

    Article  PubMed  CAS  Google Scholar 

  53. Bukulmez O et al (2008) Inflammatory status influences aromatase and steroid receptor expression in endometriosis. Endocrinology 149:1190–1204

    Article  PubMed  CAS  Google Scholar 

  54. Bussaglia E et al (2000) PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31:312–317

    Article  PubMed  CAS  Google Scholar 

  55. Byron SA et al (2008) Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation. Cancer Res 68:6902–6907

    Article  PubMed  CAS  Google Scholar 

  56. Caduff RF, Johnston CM, Frank TS (1995) Mutations of the Ki-ras oncogene in carcinoma of the endometrium. Am J Pathol 146:182–188

    PubMed  CAS  Google Scholar 

  57. Callister M et al (2004) Malignant mixed Mullerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome. Int J Radiat Oncol Biol Phys 58:786–796

    Article  PubMed  Google Scholar 

  58. Carcangiu ML, Chambers JT (1992) Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol 47:298–305

    Article  PubMed  CAS  Google Scholar 

  59. Carcangiu ML et al (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part I: Clinical and histologic correlations. Am J Clin Pathol 94:247–254

    PubMed  CAS  Google Scholar 

  60. Carcangiu ML et al (2006) HNPCC-related endometrial carcinomas show a high frequency of non-endometrioid types and of high FIGO grade endometrioid carcinomas. Mod Pathol 19:173A

    Google Scholar 

  61. Carcangiu ML, Tan LK, Chambers JT (1997) Stage IA uterine serous carcinoma: a study of 13 cases. Am J Surg Pathol 21:1507–1514

    Article  PubMed  CAS  Google Scholar 

  62. Castrillon DH, Lee KR, Nucci MR (2002) Distinction between endometrial and endocervical adenocarcinoma: an immunohistochemical study. Int J Gynecol Pathol 21:4–10

    Article  PubMed  Google Scholar 

  63. Catasus L et al (2004) Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol 35:1360–1368

    Article  PubMed  CAS  Google Scholar 

  64. Chakravarty D et al (2007) Estrogen receptor beta1 and the beta2/betacx isoforms in nonneoplastic endometrium and in endometrioid carcinoma. Int J Gynecol Cancer 17:905–913

    Article  PubMed  CAS  Google Scholar 

  65. Chambers JT et al (1990) Immunohistochemical evaluation of estrogen and progesterone receptor content in 183 patients with endometrial carcinoma. Part II: Correlation between biochemical and immunohistochemical methods and survival. Am J Clin Pathol 94:255–260

    PubMed  CAS  Google Scholar 

  66. Chan JK, Kapp DS (2007) Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 8:831–841

    Article  PubMed  Google Scholar 

  67. Chan JK et al (2007) The impact of the absolute number and ratio of positive lymph nodes on survival of endometrioid uterine cancer patients. Br J Cancer 97:605–611

    Article  PubMed  CAS  Google Scholar 

  68. Chan WK et al (1995) Nuclear and cytoplasmic bcl-2 expression in endometrial hyperplasia and adenocarcinoma. J Pathol 177:241–246

    Article  PubMed  CAS  Google Scholar 

  69. Chen JL, Trost DC, Wilkinson EJ (1985) Endometrial papillary adenocarcinomas: two clinicopathological types. Int J Gynecol Pathol 4:279–288

    Article  PubMed  CAS  Google Scholar 

  70. Chen KT, Kostich ND, Rosai J (1978) Peritoneal foreign body granulomas to keratin in uterine adenocanthoma. Arch Pathol Lab Med 102:174–177

    PubMed  CAS  Google Scholar 

  71. Chi DS et al (2008) The incidence of pelvic lymph node metastasis by FIGO staging for patients with adequately surgically staged endometrial adenocarcinoma of endometrioid histology. Int J Gynecol Cancer 18:269–273

    Article  PubMed  CAS  Google Scholar 

  72. Chieng DC, Ross JS, Ambros RA (1996) bcl-2 expression and the development of endometrial carcinoma. Mod Pathol 9:402–406

    Google Scholar 

  73. Chiesa-Vottero AG et al (2007) Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma. Int J Gynecol Pathol 26:328–333

    Article  PubMed  Google Scholar 

  74. Christopherson WM, Alberhasky RC, Connelly PJ (1982) Carcinoma of the endometrium: I. A clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer 49:1511–1523

    Article  PubMed  CAS  Google Scholar 

  75. Christopherson WM, Alberhasky RC, Connelly PJ (1982) Carcinoma of the endometrium. II. Papillary adenocarcinoma: a clinical pathological study, 46 cases. Am J Clin Pathol 77:534–540

    PubMed  CAS  Google Scholar 

  76. Christopherson WM, Alberhasky RC, Connelly PJ (1982) Glassy cell carcinoma of the endometrium. Hum Pathol 13:418–421

    Article  PubMed  CAS  Google Scholar 

  77. Christopherson WM, Connelly PJ, Alberhasky RC (1983) Carcinoma of the endometrium. V. An analysis of prognosticators in patients with favorable subtypes and Stage I disease. Cancer 51:1705–1709

    Article  PubMed  CAS  Google Scholar 

  78. Chuang JT, Van Velden DJ, Graham JB (1970) Carcinosarcoma and mixed mesodermal tumor of the uterine corpus. Review of 49 cases. Obstet Gynecol 35:769–780

    PubMed  CAS  Google Scholar 

  79. Cimbaluk D et al (2007) Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets. Gynecol Oncol 105:138–144

    Article  PubMed  CAS  Google Scholar 

  80. Cirisano FD Jr et al (1999) Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma. Gynecol Oncol 74:385–394

    Article  PubMed  Google Scholar 

  81. Cirisano FD Jr et al (2000) The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma. Gynecol Oncol 77:55–65

    Article  PubMed  Google Scholar 

  82. Clement PB, Scully RE (1990) Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases with a review of the literature. Hum Pathol 21:363–381

    Article  PubMed  CAS  Google Scholar 

  83. Connell PP et al (1999) Race and clinical outcome in endometrial carcinoma. Obstet Gynecol 94:713–720

    Article  PubMed  CAS  Google Scholar 

  84. Connelly PJ, Alberhasky RC, Christopherson WM (1982) Carcinoma of the endometrium. III. Analysis of 865 cases of adenocarcinoma and adenoacanthoma. Obstet Gynecol 59:569–575

    PubMed  CAS  Google Scholar 

  85. Connor EE et al (2007) Regulation of gene expression in the bovine mammary gland by ovarian steroids. J Dairy Sci 90(Suppl 1):E55–E65

    Article  PubMed  Google Scholar 

  86. Cook LS et al (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359–1364

    Article  PubMed  CAS  Google Scholar 

  87. Coppola D et al (1998) Prognostic significance of p53, bcl-2, vimentin, and S100 protein-positive Langerhans cells in endometrial carcinoma. Hum Pathol 29:455–462

    Article  PubMed  CAS  Google Scholar 

  88. Cork DM, Lennard TW, Tyson-Capper AJ (2008) Alternative splicing and the progesterone receptor in breast cancer. Breast Cancer Res 10:207

    Article  PubMed  CAS  Google Scholar 

  89. Creasman WT (1989) Announcement. FIGO stages: 1988 revision. Gynecol Oncol 35:125–127

    Article  Google Scholar 

  90. Creasman WT (1997) Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol 24:S1-140–S1-150

    Google Scholar 

  91. Creasman WT et al (1999) Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. Am J Obstet Gynecol 181:31–34

    Article  PubMed  CAS  Google Scholar 

  92. Creasman WT et al (1981) Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol 141:921–929

    PubMed  CAS  Google Scholar 

  93. Creasman WT et al (1986) Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol 67:326–330

    PubMed  CAS  Google Scholar 

  94. Creasman WT et al (1987) Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer 60:2035–2041

    Article  PubMed  CAS  Google Scholar 

  95. Creasman WT et al (2003) Carcinoma of the corpus uteri. Int J Gynaecol Obstet 83(Suppl 1):79–118

    Article  PubMed  Google Scholar 

  96. Crissman JD et al (1981) Endometrial carcinoma in women 40 years of age or younger. Obstet Gynecol 57:699–704

    PubMed  CAS  Google Scholar 

  97. Curtis RE et al (2004) Risk of malignant mixed mullerian tumors after tamoxifen therapy for breast cancer. J Natl Cancer Inst 96:70–74

    Article  PubMed  CAS  Google Scholar 

  98. Czernobilsky B et al (1980) Endocervical-type epithelium in endometrial carcinoma: a report of 10 cases with emphasis on histochemical methods for differential diagnosis. Am J Surg Pathol 4:481–489

    Article  PubMed  CAS  Google Scholar 

  99. Daniel AG, Peters WA 3rd (1988) Accuracy of office and operating room curettage in the grading of endometrial carcinoma. Obstet Gynecol 71:612–614

    PubMed  CAS  Google Scholar 

  100. Darvishian F et al (2004) Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopathologic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol 28:1568–1578

    Article  PubMed  Google Scholar 

  101. de Leeuw WJ et al (2000) Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. J Pathol 192:328–335

    Article  PubMed  Google Scholar 

  102. Deligdisch L, Holinka CF (1986) Progesterone receptors in two groups of endometrial carcinoma. Cancer 57:1385–1388

    Article  PubMed  CAS  Google Scholar 

  103. Demczuk S et al (2003) The comparison of the agreement in determining the histological grade of uterine endometrial endometrioid carcinoma, using the three-grade FIGO classification and the two-grade system. Pol J Pathol 54:179–181

    PubMed  Google Scholar 

  104. Demopoulos RI et al (1996) Papillary carcinoma of the endometrium: morphometric predictors of survival. Int J Gynecol Pathol 15:110–118

    Article  PubMed  CAS  Google Scholar 

  105. Dockerty MB, Lovelady SB, Foust GT Jr (1951) Carcinoma of the corpus uteri in young women. Am J Obstet Gynecol 61:966–981

    PubMed  CAS  Google Scholar 

  106. Doering DL et al (1989) Intraoperative evaluation of depth of myometrial invasion in stage I endometrial adenocarcinoma. Obstet Gynecol 74:930–933

    PubMed  CAS  Google Scholar 

  107. Duggan BD et al (1994) Microsatellite instability in sporadic endometrial carcinoma. J Natl Cancer Inst 86:1216–1221

    Article  PubMed  CAS  Google Scholar 

  108. Dunton CJ et al (1991) Uterine papillary serous carcinoma: a review. Obstet Gynecol Surv 46:97–102

    Article  PubMed  CAS  Google Scholar 

  109. Egan JA et al (2004) Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium. Int J Gynecol Pathol 23:119–122

    Article  PubMed  Google Scholar 

  110. Ehrlich CE et al (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158:796–807

    PubMed  CAS  Google Scholar 

  111. Eifel P et al (1982) Simultaneous presentation of carcinoma involving the ovary and the uterine corpus. Cancer 50:163–170

    Article  PubMed  CAS  Google Scholar 

  112. Eifel PJ et al (1983) Adenocarcinoma of the endometrium. Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer 52:1026–1031

    Article  PubMed  CAS  Google Scholar 

  113. Enomoto T et al (1993) Alterations of the p53 tumor suppressor gene and its association with activation of the c-K-ras-2 protooncogene in premalignant and malignant lesions of the human uterine endometrium. Cancer Res 53:1883–1888

    PubMed  CAS  Google Scholar 

  114. Enriori CL, Reforzo-Membrives J (1984) Peripheral aromatization as a risk factor for breast and endometrial cancer in postmenopausal women: a review. Gynecol Oncol 17:1–21

    Article  PubMed  CAS  Google Scholar 

  115. Eshleman JR, Markowitz SD (1995) Microsatellite instability in inherited and sporadic neoplasms. Curr Opin Oncol 7:83–89

    PubMed  CAS  Google Scholar 

  116. Esteller M et al (1999) MLH1 promoter hypermethylation is an early event in human endometrial tumorigenesis. Am J Pathol 155:1767–1772

    Article  PubMed  CAS  Google Scholar 

  117. Esteller M et al (1997) The clinicopathological significance of K-RAS point mutation and gene amplification in endometrial cancer. Eur J Cancer 33:1572–1577

    Article  PubMed  CAS  Google Scholar 

  118. Esteller M et al (1998) MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 17:2413–2417

    Article  PubMed  CAS  Google Scholar 

  119. Fader AN et al (2009) Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma. Cancer 115:2119–2127

    Article  PubMed  CAS  Google Scholar 

  120. Fanning J et al (1991) Prognostic significance of the extent of cervical involvement by endometrial cancer. Gynecol Oncol 40:46–47

    Article  PubMed  CAS  Google Scholar 

  121. Farhi DC, Nosanchuk J, Silverberg SG (1986) Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 68:741–745

    PubMed  CAS  Google Scholar 

  122. Farley JH et al (2000) Age-specific survival of women with endometrioid adenocarcinoma of the uterus. Gynecol Oncol 79:86–89

    Article  PubMed  CAS  Google Scholar 

  123. Ferguson SE et al (2007) Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol 31:382–389

    Article  PubMed  Google Scholar 

  124. Ferguson SE et al (2006) Comparison of uterine malignancies that develop during and following tamoxifen therapy. Gynecol Oncol 101:322–326

    Article  PubMed  CAS  Google Scholar 

  125. Ferguson SE et al (2007) Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol 31:1653–1661

    Article  PubMed  Google Scholar 

  126. Fersis N et al (2004) Sentinel node identification and intraoperative lymphatic mapping. First results of a pilot study in patients with endometrial cancer. Eur J Gynaecol Oncol 25:339–342

    PubMed  CAS  Google Scholar 

  127. Fisher B et al (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537

    Article  PubMed  CAS  Google Scholar 

  128. Fisher B et al (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388

    Article  PubMed  CAS  Google Scholar 

  129. Fleming WP et al (1984) Autopsy findings in patients with uterine sarcoma. Gynecol Oncol 19:168–172

    Article  PubMed  CAS  Google Scholar 

  130. Fornander T et al (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117–120

    Article  PubMed  CAS  Google Scholar 

  131. Franks AL, Kendrick JS, Tyler CW Jr (1987) Postmenopausal smoking, estrogen replacement therapy, and the risk of endometrial cancer. Am J Obstet Gynecol 156:20–23

    PubMed  CAS  Google Scholar 

  132. Fujii H et al (2000) Frequent genetic heterogeneity in the clonal evolution of gynecological carcinosarcoma and its influence on phenotypic diversity. Cancer Res 60:114–120

    PubMed  CAS  Google Scholar 

  133. Fukuchi T et al (1998) Beta-catenin mutation in carcinoma of the uterine endometrium. Cancer Res 58:3526–3528

    PubMed  CAS  Google Scholar 

  134. Fukuda K et al (1998) Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 69:220–225

    Article  PubMed  CAS  Google Scholar 

  135. Fuqua SA, Cui Y (2004) Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res Treat 87(Suppl 1):S3–S10

    Article  PubMed  CAS  Google Scholar 

  136. Gagne E et al (1989) Morphologic prognostic factors of malignant mixed mullerian tumor of the uterus: a clinicopathologic study of 58 cases. Mod Pathol 2:433–438

    PubMed  CAS  Google Scholar 

  137. Gal D, Recio FO, Zamurovic D (1992) The new International Federation of Gynecology and Obstetrics surgical staging and survival rates in early endometrial carcinoma. Cancer 69:200–202

    Article  PubMed  CAS  Google Scholar 

  138. Gal D et al (1991) Lymphvascular space involvement – a prognostic indicator in endometrial adenocarcinoma. Gynecol Oncol 42:142–145

    Article  PubMed  CAS  Google Scholar 

  139. Gambrell RD Jr, Bagnell CA, Greenblatt RB (1983) Role of estrogens and progesterone in the etiology and prevention of endometrial cancer: review. Am J Obstet Gynecol 146:696–707

    PubMed  CAS  Google Scholar 

  140. Garg K et al (2009) Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 33:925–933

    Article  PubMed  Google Scholar 

  141. Garzetti GG et al (1996) Proliferating cell nuclear antigen in endometrial carcinoma: pretreatment identification of high-risk patients. Gynecol Oncol 61:16–21

    Article  PubMed  CAS  Google Scholar 

  142. Gasparini GS, Fea RP (1992) Multivariate analysis of prognostic factors in 232 patients with clinical stage I endometrial carcinoma using the new FIGO surgical staging system. Int J Oncol 1:665–672

    PubMed  CAS  Google Scholar 

  143. Gates EJ et al (2006) Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc 98:1814–1822

    PubMed  Google Scholar 

  144. Geisinger KR et al (1986) Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 58:1518–1525

    Article  PubMed  CAS  Google Scholar 

  145. Geisinger KR et al (1986) Correlation of female sex steroid hormone receptors with histologic and ultrastructural differentiation in adenocarcinoma of the endometrium. Cancer 58:1506–1517

    Article  PubMed  CAS  Google Scholar 

  146. Geisler JP et al (1998) Lack of bcl-2 persistence: an independent prognostic indicator of poor prognosis in endometrial carcinoma. Gynecol Oncol 71:305–307

    Article  PubMed  CAS  Google Scholar 

  147. Geisler JP et al (1996) p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 61:245–248

    Article  PubMed  CAS  Google Scholar 

  148. George E et al (1995) Malignant mixed mullerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival. Int J Gynecol Pathol 14:39–44

    Article  PubMed  CAS  Google Scholar 

  149. Giangrande PH, McDonnell DP (1999) The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. Recent Prog Horm Res 54:291–313; discussion 313–314

    PubMed  CAS  Google Scholar 

  150. Gitsch G et al (1995) Uterine papillary serous carcinoma. A clinical study. Cancer 75:2239–2243

    Article  PubMed  CAS  Google Scholar 

  151. Gitsch G et al (1995) Endometrial cancer in premenopausal women 45 years and younger. Obstet Gynecol 85:504–508

    Article  PubMed  CAS  Google Scholar 

  152. Goldstein NS, Uzieblo A (2002) WT1 immunoreactivity in uterine papillary serous carcinomas is different from ovarian serous carcinomas. Am J Clin Pathol 117:541–545

    Article  PubMed  Google Scholar 

  153. Gompel A et al (1994) Bcl-2 expression in normal endometrium during the menstrual cycle. Am J Pathol 144:1195–1202

    PubMed  CAS  Google Scholar 

  154. Goodman A et al (1996) Squamous cell carcinoma of the endometrium: a report of eight cases and a review of the literature. Gynecol Oncol 61:54–60

    Article  PubMed  CAS  Google Scholar 

  155. Gray LA Sr, Christopherson WM, Hoover RN (1977) Estrogens and endometrial carcinoma. Obstet Gynecol Surv 32:619–621

    Article  PubMed  Google Scholar 

  156. Greenblatt RB, Gambrell RD Jr, Stoddard LD (1982) The protective role of progesterone in the prevention of endometrial cancer. Pathol Res Pract 174:297–318

    Article  PubMed  CAS  Google Scholar 

  157. Greenwald P, Caputo TA, Wolfgang PE (1977) Endometrial cancer after menopausal use of estrogens. Obstet Gynecol 50:239–243

    PubMed  CAS  Google Scholar 

  158. Greven KM et al (1993) Pathologic stage III endometrial carcinoma. Prognostic factors and patterns of recurrence. Cancer 71:3697–3702

    Article  PubMed  CAS  Google Scholar 

  159. Grimshaw RN et al (1990) Prognostic value of peritoneal cytology in endometrial carcinoma. Gynecol Oncol 36:97–100

    Article  PubMed  CAS  Google Scholar 

  160. Gronroos M et al (1993) Mass screening for endometrial cancer directed in risk groups of patients with diabetes and patients with hypertension. Cancer 71:1279–1282

    Article  PubMed  CAS  Google Scholar 

  161. Gu M et al (2000) Peritoneal washings in endometrial carcinoma. A study of 298 patients with histopathologic correlation. Acta Cytol 44:783–789

    Article  PubMed  CAS  Google Scholar 

  162. Guidi AJ et al (1996) Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in endometrial carcinoma. Cancer 78:454–460

    Article  PubMed  CAS  Google Scholar 

  163. Hagiwara T, Mori T, Kaku T (2005) Development of endometrial cancer following radiation therapy for cervical carcinoma. Eur J Gynaecol Oncol 26:191–195

    PubMed  CAS  Google Scholar 

  164. Hall JB, Young RH, Nelson JH Jr (1984) The prognostic significance of adenomyosis in endometrial carcinoma. Gynecol Oncol 17:32–40

    Article  PubMed  CAS  Google Scholar 

  165. Hamel NW et al (1996) Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 62:192–198

    Article  PubMed  CAS  Google Scholar 

  166. Hampel H et al (2006) Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 66:7810–7817

    Article  PubMed  CAS  Google Scholar 

  167. Hanson MB et al (1985) The prognostic significance of lymph-vascular space invasion in stage I endometrial cancer. Cancer 55:1753–1757

    Article  PubMed  CAS  Google Scholar 

  168. Harouny VR et al (1988) The importance of peritoneal cytology in endometrial carcinoma. Obstet Gynecol 72:394–398

    PubMed  CAS  Google Scholar 

  169. Hayes MP, Douglas W, Ellenson LH (2009) Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol Oncol 113:370–373

    Article  PubMed  CAS  Google Scholar 

  170. Hayes MP et al (2006) PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12:5932–5935

    Article  PubMed  CAS  Google Scholar 

  171. Heatley MK (1997) A high apoptotic index occurs in subtypes of endometrial adenocarcinoma associated with a poor prognosis. Pathology 29:272–275

    Article  PubMed  CAS  Google Scholar 

  172. Heatley MK (1995) Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathology 27:469–472

    Article  PubMed  CAS  Google Scholar 

  173. Henderson GS et al (1996) bcl-2 is down-regulated in atypical endometrial hyperplasia and adenocarcinoma. Mod Pathol 9:430–438

    PubMed  CAS  Google Scholar 

  174. Hendrickson M et al (1982) Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol 6:93–108

    Article  PubMed  CAS  Google Scholar 

  175. Hendrickson MR, Kempson RL (1983) Ciliated carcinoma – a variant of endometrial adenocarcinoma: a report of 10 cases. Int J Gynecol Pathol 2:1–12

    Article  PubMed  CAS  Google Scholar 

  176. Hernandez E, Woodruff JD (1980) Endometrial adenocarcinoma arising in adenomyosis. Am J Obstet Gynecol 138:827–832

    PubMed  CAS  Google Scholar 

  177. Hetzel DJ et al (1992) HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol Oncol 47:179–185

    Article  PubMed  CAS  Google Scholar 

  178. Hicks ML et al (1998) The National Cancer Data Base report on endometrial carcinoma in African-American women. Cancer 83:2629–2637

    Article  PubMed  CAS  Google Scholar 

  179. Hoffman MS et al (1989) Adenocarcinoma of the endometrium and endometrioid carcinoma of the ovary associated with pregnancy. Gynecol Oncol 32:82–85

    Article  PubMed  CAS  Google Scholar 

  180. Homesley HD, Zaino R (1994) Endometrial cancer: prognostic factors. Semin Oncol 21:71–78

    PubMed  CAS  Google Scholar 

  181. Hopp TA et al (2004) Breast cancer patients with progesterone receptor PR-A-rich tumors have poorer disease-free survival rates. Clin Cancer Res 10:2751–2760

    Article  PubMed  CAS  Google Scholar 

  182. Hornback NB, Omura G, Major FJ (1986) Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys 12:2127–2130

    Article  PubMed  CAS  Google Scholar 

  183. Horwitz RI et al (1981) Necropsy diagnosis of endometrial cancer and detection-bias in case/control studies. Lancet 2:66–68

    Article  PubMed  CAS  Google Scholar 

  184. Hoshida Y et al (1996) Hepatoid adenocarcinoma of the endometrium associated with alpha-fetoprotein production. Int J Gynecol Pathol 15:266–269

    Article  PubMed  CAS  Google Scholar 

  185. Ingle JN (1994) Tamoxifen and endometrial cancer: new challenges for an “old” drug. Gynecol Oncol 55:161–163

    Article  PubMed  CAS  Google Scholar 

  186. Inoue Y et al (1996) The prognostic significance of vascular invasion by endometrial carcinoma. Cancer 78:1447–1451

    Article  PubMed  CAS  Google Scholar 

  187. Inthasorn P et al (2002) Analysis of clinicopathologic factors in malignant mixed Mullerian tumors of the uterine corpus. Int J Gynecol Cancer 12:348–353

    Article  PubMed  CAS  Google Scholar 

  188. Ioffe OB, Papadimitriou JC, Drachenberg CB (1998) Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 29:1150–1159

    Article  PubMed  CAS  Google Scholar 

  189. Ismail SM (1996) The effects of tamoxifen on the uterus. Curr Opin Obstet Gynecol 8:27–31

    Article  PubMed  CAS  Google Scholar 

  190. Ito K et al (1997) Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183:318–324

    Article  PubMed  CAS  Google Scholar 

  191. Ito K et al (1996) K-ras point mutations in endometrial carcinoma: effect on outcome is dependent on age of patient. Gynecol Oncol 63:238–246

    Article  PubMed  CAS  Google Scholar 

  192. Ito K et al (1994) Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 54:4667–4670

    PubMed  CAS  Google Scholar 

  193. Iversen OE (1986) Flow cytometric deoxyribonucleic acid index: a prognostic factor in endometrial carcinoma. Am J Obstet Gynecol 155:770–776

    PubMed  CAS  Google Scholar 

  194. Jacobsen BM et al (2005) Progesterone-independent effects of human progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene regulation and tumor biology. Mol Endocrinol 19:574–587

    Article  PubMed  CAS  Google Scholar 

  195. Jacques SM, Lawrence WD (1990) Endometrial adenocarcinoma with variable-level myometrial involvement limited to adenomyosis: a clinicopathologic study of 23 cases. Gynecol Oncol 37:401–407

    Article  PubMed  CAS  Google Scholar 

  196. Jones MA, Young RH, Scully RE (1991) Endometrial adenocarcinoma with a component of giant cell carcinoma. Int J Gynecol Pathol 10:260–270

    Article  PubMed  CAS  Google Scholar 

  197. Jones MW et al (1997) Prognostic value of p53 and K-ras-2 topographic genotyping in endometrial carcinoma: a clinicopathologic and molecular comparison. Int J Gynecol Pathol 16:354–360

    Article  PubMed  CAS  Google Scholar 

  198. Jordan LB, Al-Nafussi A (2002) Clinicopathological study of the pattern and significance of cervical involvement in cases of endometrial adenocarcinoma. Int J Gynecol Cancer 12:42–48

    Article  PubMed  CAS  Google Scholar 

  199. Jordan VC, Morrow M (1994) Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 30A:1714–1721

    Article  PubMed  CAS  Google Scholar 

  200. Joseph MG, Fellows FG, Hearn SA (1990) Primary endodermal sinus tumor of the endometrium. A clinicopathologic, immunocytochemical, and ultrastructural study. Cancer 65:297–302

    Article  PubMed  CAS  Google Scholar 

  201. Kadar N, Homesley HD, Malfetano JH (1992) Positive peritoneal cytology is an adverse factor in endometrial carcinoma only if there is other evidence of extrauterine disease. Gynecol Oncol 46:145–149

    Article  PubMed  CAS  Google Scholar 

  202. Kadar N, Malfetano JH, Homesley HD (1993) Steroid receptor concentrations in endometrial carcinoma: effect on survival in surgically staged patients. Gynecol Oncol 50:281–286

    Article  PubMed  CAS  Google Scholar 

  203. Kaku T et al (1997) Angiogenesis in endometrial carcinoma. Cancer 80:741–747

    Article  PubMed  CAS  Google Scholar 

  204. Kaku T et al (1993) Association of endometrial epithelial metaplasias with endometrial carcinoma and hyperplasia in Japanese and American women. Int J Gynecol Pathol 12:297–300

    Article  PubMed  CAS  Google Scholar 

  205. Kaleli S et al (1997) A strong prognostic variable in endometrial carcinoma: flow cytometric S-phase fraction. Cancer 79:944–951

    Article  PubMed  CAS  Google Scholar 

  206. Kalir T et al (1995) Endometrial adenocarcinoma with choriocarcinomatous differentiation in an elderly virginal woman. Int J Gynecol Pathol 14:266–269

    Article  PubMed  CAS  Google Scholar 

  207. Kallakury BV et al (1998) Cell proliferation-associated proteins in endometrial carcinomas, including papillary serous and endometrioid subtypes. Int J Gynecol Pathol 17:320–326

    Article  PubMed  CAS  Google Scholar 

  208. Kanbour-Shakir A, Tobon H (1991) Primary clear cell carcinoma of the endometrium: a clinicopathologic study of 20 cases. Int J Gynecol Pathol 10:67–78

    Article  PubMed  CAS  Google Scholar 

  209. Kapucuoglu N et al (2008) Reproducibility of grading systems for endometrial endometrioid carcinoma and their relation with pathologic prognostic parameters. Int J Gynecol Cancer 18:790–796

    Article  PubMed  CAS  Google Scholar 

  210. Katase K et al (1998) The incidence of subsequent endometrial carcinoma with tamoxifen use in patients with primary breast carcinoma. Cancer 82:1698–1703

    Article  PubMed  CAS  Google Scholar 

  211. Kaufman DW et al (1980) Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 303:1045–1047

    Article  PubMed  CAS  Google Scholar 

  212. Kelly MG et al (2004) Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation. Gynecol Oncol 95:469–473

    Article  PubMed  CAS  Google Scholar 

  213. Kelly MG et al (2005) Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 98:353–359

    Article  PubMed  CAS  Google Scholar 

  214. Kennedy AW et al (1987) Experience with pelvic washings in stage I and II endometrial carcinoma. Gynecol Oncol 28:50–60

    Article  PubMed  CAS  Google Scholar 

  215. Khalifa MA et al (1994) Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 53:84–92

    Article  PubMed  CAS  Google Scholar 

  216. Khuu HM et al (2000) Carcinosarcoma of the uterus associated with a nongestational choriocarcinoma. South Med J 93:226–228

    PubMed  CAS  Google Scholar 

  217. Kihana T et al (1995) Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 76:72–78

    Article  PubMed  CAS  Google Scholar 

  218. Kim KR, Scully RE (1990) Peritoneal keratin granulomas with carcinomas of endometrium and ovary and atypical polypoid adenomyoma of endometrium. A clinicopathological analysis of 22 cases. Am J Surg Pathol 14:925–932

    Article  PubMed  CAS  Google Scholar 

  219. Klemi PJ, Alanen KA, Salmi T (1995) Detection of malignancy in endometrium by brush sampling in 1042 symptomatic patients. Int J Gynecol Cancer 5:222–225

    Article  PubMed  Google Scholar 

  220. Kobayashi K et al (1999) Mutations of the beta-catenin gene in endometrial carcinomas. Jpn J Cancer Res 90:55–59

    Article  PubMed  CAS  Google Scholar 

  221. Kohlberger P et al (1996) p53 protein overexpression in early stage endometrial cancer. Gynecol Oncol 62:213–217

    Article  PubMed  CAS  Google Scholar 

  222. Kohler MF et al (1996) p53 overexpression in advanced-stage endometrial adenocarcinoma. Am J Obstet Gynecol 175:1246–1252

    Article  PubMed  CAS  Google Scholar 

  223. Kommoss F et al (1998) Steroid receptor expression in endometria from women treated with tamoxifen. Gynecol Oncol 70:188–191

    Article  PubMed  CAS  Google Scholar 

  224. Kosary CL (1994) FIGO stage, histology, histologic grade, age and race as prognostic factors in determining survival for cancers of the female gynecological system: an analysis of 1973–87 SEER cases of cancers of the endometrium, cervix, ovary, vulva, and vagina. Semin Surg Oncol 10:31–46

    Article  PubMed  CAS  Google Scholar 

  225. Koshiyama M et al (1993) Immunohistochemical analysis of p53 protein over-expression in endometrial carcinomas: inverse correlation with sex steroid receptor status. Virchows Arch A Pathol Anat Histopathol 423:265–271

    Article  PubMed  CAS  Google Scholar 

  226. Koss LG et al (1984) Detection of endometrial carcinoma and hyperplasia in asymptomatic women. Obstet Gynecol 64:1–11

    PubMed  CAS  Google Scholar 

  227. Kovalev S et al (1998) Loss of p53 function in uterine papillary serous carcinoma. Hum Pathol 29:613–619

    Article  PubMed  CAS  Google Scholar 

  228. Kumar NB, Hart WR (1982) Metastases to the uterine corpus from extragenital cancers. A clinicopathologic study of 63 cases. Cancer 50:2163–2169

    Article  PubMed  CAS  Google Scholar 

  229. Kurman RJ, Scully RE (1976) Clear cell carcinoma of the endometrium: an analysis of 21 cases. Cancer 37:872–882

    Article  PubMed  CAS  Google Scholar 

  230. Lacey JV Jr et al (2008) PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 68:6014–6020

    Article  PubMed  CAS  Google Scholar 

  231. Larson B et al (1990) Mixed mullerian tumours of the uterus–prognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol 17:123–132

    Article  PubMed  CAS  Google Scholar 

  232. Larson DM et al (1995) Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 86:38–42

    Article  PubMed  CAS  Google Scholar 

  233. Lauchlan SC (1981) Tubal (serous) carcinoma of the endometrium. Arch Pathol Lab Med 105:615–618

    PubMed  CAS  Google Scholar 

  234. Lax SF et al (2000) The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrioid and serous carcinoma: evidence of distinct molecular genetic pathways. Cancer 88:814–824

    Article  PubMed  CAS  Google Scholar 

  235. Lax SF et al (2000) A binary architectural grading system for uterine endometrial endometrioid carcinoma has superior reproducibility compared with FIGO grading and identifies subsets of advance-stage tumors with favorable and unfavorable prognosis. Am J Surg Pathol 24:1201–1208

    Article  PubMed  CAS  Google Scholar 

  236. Lax SF et al (1998) Clear cell carcinoma of the endometrium is characterized by a distinctive profile of p53, Ki-67, estrogen, and progesterone receptor expression. Hum Pathol 29:551–558

    Article  PubMed  CAS  Google Scholar 

  237. Lax SF et al (1998) Comparison of estrogen and progesterone receptor, Ki-67, and p53 immunoreactivity in uterine endometrioid carcinoma and endometrioid carcinoma with squamous, mucinous, secretory, and ciliated cell differentiation. Hum Pathol 29:924–931

    Article  PubMed  CAS  Google Scholar 

  238. Lee KR, Belinson JL (1991) Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma. Am J Surg Pathol 15:965–973

    Article  PubMed  CAS  Google Scholar 

  239. Lee KR, Scully RE (1989) Complex endometrial hyperplasia and carcinoma in adolescents and young women 15 to 20 years of age. A report of 10 cases. Int J Gynecol Pathol 8:201–213

    Article  PubMed  CAS  Google Scholar 

  240. Lee KR, Vacek PM, Belinson JL (1994) Traditional and nontraditional histopathologic predictors of recurrence in uterine endometrioid adenocarcinoma. Gynecol Oncol 54:10–18

    Article  PubMed  CAS  Google Scholar 

  241. Lee RB, Burke TW, Park RC (1990) Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol 36:189–191

    Article  PubMed  CAS  Google Scholar 

  242. Leiserowitz GS et al (1993) The proto-oncogene c-fms is overexpressed in endometrial cancer. Gynecol Oncol 49:190–196

    Article  PubMed  CAS  Google Scholar 

  243. Lesko SM et al (1985) Cigarette smoking and the risk of endometrial cancer. N Engl J Med 313:593–596

    Article  PubMed  CAS  Google Scholar 

  244. Levenback C et al (1992) Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC). Gynecol Oncol 46:317–321

    Article  PubMed  CAS  Google Scholar 

  245. Levi F et al (1993) Dietary factors and the risk of endometrial cancer. Cancer 71:3575–3581

    Article  PubMed  CAS  Google Scholar 

  246. Levine RL et al (1998) PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 58:3254–3258

    PubMed  CAS  Google Scholar 

  247. Li J et al (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943–1947

    Article  PubMed  CAS  Google Scholar 

  248. Lininger RA et al (1997) Transitional cell carcinoma of the endometrium and endometrial carcinoma with transitional cell differentiation. Cancer 79:1933–1943

    Article  PubMed  CAS  Google Scholar 

  249. Livasy CA et al (2006) EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma. Gynecol Oncol 100:101–106

    Article  PubMed  CAS  Google Scholar 

  250. Longacre TA, Hendrickson MR (1999) Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion. Am J Surg Pathol 23:69–78

    Article  PubMed  CAS  Google Scholar 

  251. Lukes AS et al (1994) Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 73:2380–2385

    Article  PubMed  CAS  Google Scholar 

  252. Macasaet MA et al (1985) Prognostic factors in malignant mesodermal (mullerian) mixed tumors of the uterus. Gynecol Oncol 20:32–42

    Article  PubMed  CAS  Google Scholar 

  253. Mack TM et al (1976) Estrogens and endometrial cancer in a retirement community. N Engl J Med 294:1262–1267

    Article  PubMed  CAS  Google Scholar 

  254. MacMahon B (1997) Overview of studies on endometrial cancer and other types of cancer in humans: perspectives of an epidemiologist. Semin Oncol 24:S1-122–S1-139

    Google Scholar 

  255. Magriples U et al (1993) High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485–490

    PubMed  CAS  Google Scholar 

  256. Mai KT et al (2002) Endometrioid carcinoma of the endometrium with an invasive component of minimal deviation carcinoma. Hum Pathol 33:856–858

    Article  PubMed  Google Scholar 

  257. Major FJ et al (1993) Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer 71:1702–1709

    Article  PubMed  CAS  Google Scholar 

  258. Malpica A et al (1995) Low-stage clear-cell carcinoma of the endometrium. Am J Surg Pathol 19:769–774

    Article  PubMed  CAS  Google Scholar 

  259. Maxwell GL et al (1998) Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias. Cancer Res 58:2500–2503

    PubMed  CAS  Google Scholar 

  260. McCarty KS Jr et al (1979) Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol 96:171–183

    PubMed  Google Scholar 

  261. McCluggage WG (2002) Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas? J Clin Pathol 55:321–325

    Article  PubMed  CAS  Google Scholar 

  262. McCluggage WG, Jenkins D (2003) p16 immunoreactivity may assist in the distinction between endometrial and endocervical adenocarcinoma. Int J Gynecol Pathol 22:231–235

    Article  PubMed  CAS  Google Scholar 

  263. McCluggage WG et al (2002) A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas. Int J Gynecol Pathol 21:11–15

    Article  PubMed  Google Scholar 

  264. McDonald TW et al (1977) Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 127:572–580

    PubMed  CAS  Google Scholar 

  265. McKenney JK, Kong CS, Longacre TA (2005) Endometrial adenocarcinoma associated with subtle lymph-vascular space invasion and lymph node metastasis: a histologic pattern mimicking intravascular and sinusoidal histiocytes. Int J Gynecol Pathol 24:73–78

    PubMed  Google Scholar 

  266. Meis JM, Lawrence WD (1990) The immunohistochemical profile of malignant mixed mullerian tumor. Overlap with endometrial adenocarcinoma. Am J Clin Pathol 94:1–7

    PubMed  CAS  Google Scholar 

  267. Melhem MF, Tobon H (1987) Mucinous adenocarcinoma of the endometrium: a clinico-pathological review of 18 cases. Int J Gynecol Pathol 6:347–355

    Article  PubMed  CAS  Google Scholar 

  268. Milosevic MF, Dembo AJ, Thomas GM (1992) The clinical significance of malignant peritoneal cytology in stage I endometrial carcinoma. Int J Gynecol Cancer 2:225–235

    Article  PubMed  Google Scholar 

  269. Missaoui N et al (2006) p16INK4A overexpression and HPV infection in uterine cervix adenocarcinoma. Virchows Arch 448:597–603

    Article  PubMed  Google Scholar 

  270. Mitchell H, Giles G, Medley G (1993) Accuracy and survival benefit of cytological prediction of endometrial carcinoma on routine cervical smears. Int J Gynecol Pathol 12:34–40

    Article  PubMed  CAS  Google Scholar 

  271. Mittal KR, Barwick KW (1993) Endometrial adenocarcinoma involving adenomyosis without true myometrial invasion is characterized by frequent preceding estrogen therapy, low histologic grades, and excellent prognosis. Gynecol Oncol 49:197–201

    Article  PubMed  CAS  Google Scholar 

  272. Modica I et al (2007) Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 31:744–751

    Article  PubMed  Google Scholar 

  273. Moll UM et al (1996) Uterine papillary serous carcinoma evolves via a p53-driven pathway. Hum Pathol 27:1295–1300

    Article  PubMed  CAS  Google Scholar 

  274. Mooney EE et al (1997) Signet-ring cell carcinoma of the endometrium: a primary tumor masquerading as a metastasis. Int J Gynecol Pathol 16:169–172

    Article  PubMed  CAS  Google Scholar 

  275. Morgan KG, Wilkinson N, Buckley CH (1996) Angiogenesis in normal, hyperplastic, and neoplastic endometrium. J Pathol 179:317–320

    Article  PubMed  CAS  Google Scholar 

  276. Morris PC et al (1995) Steroid hormone receptor content and lymph node status in endometrial cancer. Gynecol Oncol 56:406–411

    Article  PubMed  CAS  Google Scholar 

  277. Morrow CP et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55–65

    Article  PubMed  CAS  Google Scholar 

  278. Murray SK, Clement PB, Young RH (2005) Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol 29:157–166

    Article  PubMed  Google Scholar 

  279. Murray SK, Young RH, Scully RE (2003) Unusual epithelial and stromal changes in myoinvasive endometrioid adenocarcinoma: a study of their frequency, associated diagnostic problems, and prognostic significance. Int J Gynecol Pathol 22:324–333

    Article  PubMed  Google Scholar 

  280. Mutter GL et al (1996) Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res 56:4483–4486

    PubMed  CAS  Google Scholar 

  281. Nascimento AF et al (2003) The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis. Mod Pathol 16:22–27

    Article  PubMed  Google Scholar 

  282. Nazeer T et al (1995) Multivariate survival analysis of clinicopathologic features in surgical stage I endometrioid carcinoma including analysis of HER-2/neu expression. Am J Obstet Gynecol 173:1829–1834

    Article  PubMed  CAS  Google Scholar 

  283. Nelen MR et al (1999) Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet 7:267–273

    Article  PubMed  CAS  Google Scholar 

  284. Ng AB et al (1973) Mixed adenosquamous carcinoma of the endometrium. Am J Clin Pathol 59:765–781

    PubMed  CAS  Google Scholar 

  285. Nielsen AL, Nyholm HC (1994) p53 protein and c-erbB-2 protein (p185) expression in endometrial adenocarcinoma of endometrioid type. An immunohistochemical examination on paraffin sections. Am J Clin Pathol 102:76–79

    PubMed  CAS  Google Scholar 

  286. Nielsen AL, Nyholm HC (1996) The combination of p53 and age predict cancer specific death in advanced stage (FIGO Ic-IV) of endometrial carcinoma of endometrioid type. An immunohistochemical examination of growth fraction: Ki-67, MIB-1 and PC10; suppressor oncogene protein: p53; oncogene protein: p185 and age, hormone treatment, stage, and histologic grade. Eur J Obstet Gynecol Reprod Biol 70:79–85

    Article  PubMed  CAS  Google Scholar 

  287. Nielsen AL, Nyholm HC, Engel P (1994) Expression of MIB-1 (paraffin ki-67) and AgNOR morphology in endometrial adenocarcinomas of endometrioid type. Int J Gynecol Pathol 13:37–44

    Article  PubMed  CAS  Google Scholar 

  288. Nielsen AL, Thomsen HK, Nyholm HC (1991) Evaluation of the reproducibility of the revised 1988 International Federation of Gynecology and Obstetrics grading system of endometrial cancers with special emphasis on nuclear grading. Cancer 68:2303–2309

    Article  PubMed  CAS  Google Scholar 

  289. Nielsen SN et al (1989) Clinicopathologic analysis of uterine malignant mixed mullerian tumors. Gynecol Oncol 34:372–378

    Article  PubMed  CAS  Google Scholar 

  290. Niemann TH et al (1996) bcl-2 expression in endometrial hyperplasia and carcinoma. Gynecol Oncol 63:318–322

    Article  PubMed  CAS  Google Scholar 

  291. Nofech-Mozes S et al (2008) Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma. Am J Clin Pathol 129:912–917

    Article  PubMed  Google Scholar 

  292. Nordal RR et al (1997) An evaluation of prognostic factors in uterine carcinosarcoma. Gynecol Oncol 67:316–321

    Article  PubMed  CAS  Google Scholar 

  293. Nordstrom B et al (1996) Carcinoma of the endometrium: do the nuclear grade and DNA ploidy provide more prognostic information than do the FIGO and WHO classifications? Int J Gynecol Pathol 15:191–201

    Article  PubMed  CAS  Google Scholar 

  294. Norris HJ, Roth E, Taylor HB (1966) Mesenchymal tumors of the uterus. II. A clinical and pathologic study of 31 mixed mesodermal tumors. Obstet Gynecol 28:57–63

    PubMed  CAS  Google Scholar 

  295. Norris HJ, Taylor HB (1966) Mesenchymal tumors of the uterus. 3. A clinical and pathologic study of 31 carcinosarcomas. Cancer 19:1459–1465

    Article  PubMed  CAS  Google Scholar 

  296. Noumoff JS et al (1991) The ability to evaluate prognostic variables on frozen section in hysterectomies performed for endometrial carcinoma. Gynecol Oncol 42:202–208

    Article  PubMed  CAS  Google Scholar 

  297. Nyholm HC, Christensen IJ, Nielsen AL (1995) Progesterone receptor levels independently predict survival in endometrial adenocarcinoma. Gynecol Oncol 59:347–351

    Article  PubMed  CAS  Google Scholar 

  298. Obata K et al (1998) Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 58:2095–2097

    PubMed  CAS  Google Scholar 

  299. Obermair A et al (1999) Endometrial cancer: accuracy of the finding of a well differentiated tumor at dilatation and curettage compared to the findings at subsequent hysterectomy. Int J Gynecol Cancer 9:383–386

    Article  PubMed  Google Scholar 

  300. Obermair A et al (1999) Prognostic significance of tumor angiogenesis in endometrial cancer. Obstet Gynecol 93:367–371

    Article  PubMed  CAS  Google Scholar 

  301. Oda K et al (2005) High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65:10669–10673

    Article  PubMed  CAS  Google Scholar 

  302. Ozuysal S et al (2003) Angiogenesis in endometrial carcinoma: correlation with survival and clinicopathologic risk factors. Gynecol Obstet Invest 55:173–177

    Article  PubMed  Google Scholar 

  303. Pallares J et al (2005) Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 18:719–727

    Article  PubMed  CAS  Google Scholar 

  304. Parazzini F et al (1997) The epidemiology of female genital tract cancers. Int J Gynecol Cancer 7:169–181

    Article  Google Scholar 

  305. Parazzini F et al (1991) The epidemiology of endometrial cancer. Gynecol Oncol 41:1–16

    Article  PubMed  CAS  Google Scholar 

  306. Parazzini F et al (1995) Smoking and risk of endometrial cancer: results from an Italian case-control study. Gynecol Oncol 56:195–199

    Article  PubMed  CAS  Google Scholar 

  307. Park KJMPB et al (2008) Immunoprofile of adenocarcinomas of the endometrium, endocervix, and ovary with mucinous differentiation. Appl Immunohistochemistry Mol Morphol 17:8–11

    Article  Google Scholar 

  308. Peiro G et al (2002) Microsatellite instability, loss of heterozygosity, and loss of hMLH1 and hMSH2 protein expression in endometrial carcinoma. Hum Pathol 33:347–354

    Article  PubMed  CAS  Google Scholar 

  309. Persson I et al (1989) Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. BMJ 298:147–151

    Article  PubMed  CAS  Google Scholar 

  310. Pertschuk LP et al (1996) Estrogen receptor immunocytochemistry in endometrial carcinoma: a prognostic marker for survival. Gynecol Oncol 63:28–33

    Article  PubMed  CAS  Google Scholar 

  311. Pesce C et al (1991) Endometrial carcinoma with trophoblastic differentiation. An aggressive form of uterine cancer. Cancer 68:1799–1802

    Article  PubMed  CAS  Google Scholar 

  312. Peterson EP (1968) Endometrial carcinoma in young women. A clinical profile. Obstet Gynecol 31:702–707

    Article  PubMed  CAS  Google Scholar 

  313. Pfisterer J et al (1995) Prognostic value of DNA ploidy and S-phase fraction in stage I endometrial carcinoma. Gynecol Oncol 58:149–156

    Article  PubMed  CAS  Google Scholar 

  314. Photopulos GJ et al (1979) Clear cell carcinoma of the endometrium. Cancer 43:1448–1456

    Article  PubMed  CAS  Google Scholar 

  315. Pickar JH, Thorneycroft I, Whitehead M (1998) Effects of hormone replacement therapy on the endometrium and lipid parameters: a review of randomized clinical trials, 1985 to 1995. Am J Obstet Gynecol 178:1087–1099

    Article  PubMed  CAS  Google Scholar 

  316. Pisani AL et al (1995) HER-2/neu, p53, and DNA analyses as prognosticators for survival in endometrial carcinoma. Obstet Gynecol 85:729–734

    Article  PubMed  CAS  Google Scholar 

  317. Pitman MB et al (1994) Endometrioid carcinoma of the ovary and endometrium, oxyphilic cell type: a report of nine cases. Int J Gynecol Pathol 13:290–301

    Article  PubMed  CAS  Google Scholar 

  318. Plaxe SC, Saltzstein SL (1997) Impact of ethnicity on the incidence of high-risk endometrial carcinoma. Gynecol Oncol 65:8–12

    Article  PubMed  CAS  Google Scholar 

  319. Podczaski E et al (1992) Detection and patterns of treatment failure in 300 consecutive cases of “early” endometrial cancer after primary surgery. Gynecol Oncol 47:323–327

    Article  PubMed  CAS  Google Scholar 

  320. Podsypanina K et al (1999) Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci USA 96:1563–1568

    Article  PubMed  CAS  Google Scholar 

  321. Pollock PM et al (2007) Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes. Oncogene 26:7158–7162

    Article  PubMed  CAS  Google Scholar 

  322. Pothuri B et al (2006) Radiation-associated endometrial cancers are prognostically unfavorable tumors: a clinicopathologic comparison with 527 sporadic endometrial cancers. Gynecol Oncol 103:948–951

    Article  PubMed  Google Scholar 

  323. Potischman N et al (1996) Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 88:1127–1135

    Article  PubMed  CAS  Google Scholar 

  324. Powell MA et al (2002) Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer 94:2941–2952

    Article  PubMed  CAS  Google Scholar 

  325. Prat J (2004) Prognostic parameters of endometrial carcinoma. Hum Pathol 35:649–662

    Article  PubMed  Google Scholar 

  326. Raspollini MR et al (2006) Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment? Int J Gynecol Cancer 16:416–422

    Article  PubMed  CAS  Google Scholar 

  327. Raspollini MR et al (2005) COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies? Gynecol Oncol 96:159–167

    Article  PubMed  CAS  Google Scholar 

  328. Reid-Nicholson M et al (2006) Immunophenotypic diversity of endometrial adenocarcinomas: implications for differential diagnosis. Mod Pathol 19:1091–1100

    PubMed  CAS  Google Scholar 

  329. Reinartz JJ et al (1994) Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 25:1075–1083

    Article  PubMed  CAS  Google Scholar 

  330. Ribeiro G, Swindell R (1992) The Christie Hospital adjuvant tamoxifen trial. J Natl Cancer Inst Monogr 11:121–125

    PubMed  Google Scholar 

  331. Richart RM, Ferenczy A (1974) Endometrial morphologic response to hormonal environment. Gynecol Oncol 2:180–197

    Article  PubMed  CAS  Google Scholar 

  332. Rieck GC, Freites ON, Williams S (2005) Is tamoxifen associated with high-risk endometrial carcinomas? A retrospective case series of 196 women with endometrial cancer. J Obstet Gynaecol 25:39–41

    Article  PubMed  CAS  Google Scholar 

  333. Risinger JI et al (1997) PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 57:4736–4738

    PubMed  CAS  Google Scholar 

  334. Rolitsky CD et al (1999) HER-2/neu amplification and overexpression in endometrial carcinoma. Int J Gynecol Pathol 18:138–143

    Article  PubMed  CAS  Google Scholar 

  335. Ronnett BM et al (2008) Endocervical adenocarcinomas with ovarian metastases: analysis of 29 cases with emphasis on minimally invasive cervical tumors and the ability of the metastases to simulate primary ovarian neoplasms. Am J Surg Pathol 32:1835–1853

    Article  PubMed  Google Scholar 

  336. Ross JC et al (1983) Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol 7:715–729

    PubMed  CAS  Google Scholar 

  337. Rovirosa A et al (2002) Is vascular and lymphatic space invasion a main prognostic factor in uterine neoplasms with a sarcomatous component? A retrospective study of prognostic factors of 60 patients stratified by stages. Int J Radiat Oncol Biol Phys 52:1320–1329

    Article  PubMed  Google Scholar 

  338. Rutqvist LE et al (1995) Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87:645–651

    Article  PubMed  CAS  Google Scholar 

  339. Ryden S et al (1992) Long-term effects of adjuvant tamoxifen and/or radiotherapy. The South Sweden Breast Cancer Trial. Acta Oncol 31:271–274

    Article  PubMed  CAS  Google Scholar 

  340. Ryder DE (1982) Verrucous carcinoma of the endometrium – a unique neoplasm with long survival. Obstet Gynecol 59:78S–80S

    PubMed  CAS  Google Scholar 

  341. Saegusa M et al (1996) Bcl-2 expression is correlated with a low apoptotic index and associated with progesterone receptor immunoreactivity in endometrial carcinomas. J Pathol 180:275–282

    Article  PubMed  CAS  Google Scholar 

  342. Saegusa M, Okayasu I (1998) Progesterone therapy for endometrial carcinoma reduces cell proliferation but does not alter apoptosis. Cancer 83:111–121

    Article  PubMed  CAS  Google Scholar 

  343. Saffari B et al (1995) Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: correlation with overall survival. Cancer Res 55:5693–5698

    PubMed  CAS  Google Scholar 

  344. Sagae S et al (2004) The reproducibility of a binary tumor grading system for uterine endometrial endometrioid carcinoma, compared with FIGO system and nuclear grading. Oncology 67:344–350

    Article  PubMed  Google Scholar 

  345. Saito S et al (2006) Progesterone receptor isoforms as a prognostic marker in human endometrial carcinoma. Cancer Sci 97:1308–1314

    Article  PubMed  CAS  Google Scholar 

  346. Sakuragi N et al (2000) Prognostic significance of serous and clear cell adenocarcinoma in surgically staged endometrial carcinoma. Acta Obstet Gynecol Scand 79:311–316

    Article  PubMed  CAS  Google Scholar 

  347. Sakuragi N et al (1998) Bcl-2 expression and prognosis of patients with endometrial carcinoma. Int J Cancer 79:153–158

    Article  PubMed  CAS  Google Scholar 

  348. Salvesen HB, Iversen OE, Akslen LA (1998) Identification of high-risk patients by assessment of nuclear Ki-67 expression in a prospective study of endometrial carcinomas. Clin Cancer Res 4:2779–2785

    PubMed  CAS  Google Scholar 

  349. Sartori E et al (1997) Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecol Oncol 67:70–75

    Article  PubMed  CAS  Google Scholar 

  350. Savage J, Subby W, Okagaki T (1987) Adenocarcinoma of the endometrium with trophoblastic differentiation and metastases as choriocarcinoma: a case report. Gynecol Oncol 26:257–262

    Article  PubMed  CAS  Google Scholar 

  351. Sawada M et al (2003) Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 94:986–991

    Article  PubMed  CAS  Google Scholar 

  352. Schlosshauer PW, Ellenson LH, Soslow RA (2002) Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol 15:1032–1037

    Article  PubMed  Google Scholar 

  353. Schlosshauer PW et al (2000) Mutational analysis of the CTNNB1 and APC genes in uterine endometrioid carcinoma. Mod Pathol 13:1066–1071

    Article  PubMed  CAS  Google Scholar 

  354. Scholten AN et al (2004) Prognostic significance and interobserver variability of histologic grading systems for endometrial carcinoma. Cancer 100:764–772

    Article  PubMed  Google Scholar 

  355. Schwab KV et al (2009) Prospective evaluation of prognostic significance of the tumor-free distance from uterine serosa in surgically staged endometrial adenocarcinoma. Gynecol Oncol 112:146–149

    Article  PubMed  Google Scholar 

  356. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ (1994) Histologic typing of female genital tract tumors (international histological classification of tumors), 2nd edn. Springer, New York, pp 1–189

    Book  Google Scholar 

  357. Seidman JD, Chauhan S (2003) Evaluation of the relationship between adenosarcoma and carcinosarcoma and a hypothesis of the histogenesis of uterine sarcomas. Int J Gynecol Pathol 22:75–82

    Article  PubMed  Google Scholar 

  358. Seidman JD, Kurman RJ (1999) Tamoxifen and the endometrium. Int J Gynecol Pathol 18:293–296

    Article  PubMed  CAS  Google Scholar 

  359. Semczuk A et al (1998) K-ras gene point mutations in human endometrial carcinomas: correlation with clinicopathological features and patients’ outcome. J Cancer Res Clin Oncol 124:695–700

    Article  PubMed  CAS  Google Scholar 

  360. Shapiro S et al (1980) Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med 303:485–489

    Article  PubMed  CAS  Google Scholar 

  361. Sherman ME et al (1992) Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 16:600–610

    Article  PubMed  CAS  Google Scholar 

  362. Sherman ME, Bur ME, Kurman RJ (1995) p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26:1268–1274

    Article  PubMed  CAS  Google Scholar 

  363. Sherman ME et al (1997) Risk factors and hormone levels in patients with serous and endometrioid uterine carcinomas. Mod Pathol 10:963–968

    PubMed  CAS  Google Scholar 

  364. Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer. Part I. The utility of immunohistochemistry. J Mol Diagn 10:293–300

    Article  PubMed  Google Scholar 

  365. Shia J et al (2008) Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 39:116–125

    Article  PubMed  CAS  Google Scholar 

  366. Shia J et al (2009) Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary non-polyposis colorectal cancer syndrome: A two antibody panel may be as predictive as a four antibody panel. Am J Surg Pathol 33(11):1639–1645

    Article  PubMed  Google Scholar 

  367. Shim JU et al (1992) Accuracy of frozen-section diagnosis at surgery in clinical stage I and II endometrial carcinoma. Am J Obstet Gynecol 166:1335–1338

    PubMed  CAS  Google Scholar 

  368. Silva EG et al (2006) Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma? Int J Gynecol Pathol 25:52–58

    Article  PubMed  Google Scholar 

  369. Silva EG, Jenkins R (1990) Serous carcinoma in endometrial polyps. Mod Pathol 3:120–128

    PubMed  CAS  Google Scholar 

  370. Silva EG, Tornos CS, Follen-Mitchell M (1994) Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol 13:248–258

    Article  PubMed  CAS  Google Scholar 

  371. Silverberg SG (2007) The endometrium. Arch Pathol Lab Med 131:372–382

    PubMed  Google Scholar 

  372. Silverberg SG et al (1990) Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol 9:1–19

    Article  PubMed  CAS  Google Scholar 

  373. Simpkins SB et al (1998) PTEN mutations in endometrial cancers with 10q LOH: additional evidence for the involvement of multiple tumor suppressors. Gynecol Oncol 71:391–395

    Article  PubMed  CAS  Google Scholar 

  374. Sinkre P et al (2000) Endometrial endometrioid carcinomas associated with Ewing sarcoma/peripheral primitive neuroectodermal tumor. Int J Gynecol Pathol 19:127–132

    Article  PubMed  CAS  Google Scholar 

  375. Sivridis E, Buckley CH, Fox H (1987) The prognostic significance of lymphatic vascular space invasion in endometrial adenocarcinoma. Br J Obstet Gynaecol 94:991–994

    Article  PubMed  CAS  Google Scholar 

  376. Smith DC et al (1975) Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 293:1164–1167

    Article  PubMed  CAS  Google Scholar 

  377. Society AC (2000) 2000 cancer statistics. CA Cancer J Clin 50:1–64

    Google Scholar 

  378. Sorbe B, Risberg B, Frankendal B (1990) DNA ploidy, morphometry, and nuclear grade as prognostic factors in endometrial carcinoma. Gynecol Oncol 38:22–27

    Article  PubMed  CAS  Google Scholar 

  379. Soslow RA et al (2007) Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences. Am J Surg Pathol 31:979–987

    Article  PubMed  Google Scholar 

  380. Soslow RA, Pirog E, Isacson C (2000) Endometrial intraepithelial carcinoma with associated peritoneal carcinomatosis. Am J Surg Pathol 24:726–732

    Article  PubMed  CAS  Google Scholar 

  381. Soslow RA et al (1998) Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 17:129–134

    Article  PubMed  CAS  Google Scholar 

  382. Soslow RA et al (2000) Cyclin D1 expression in high-grade endometrial carcinomas–association with histologic subtype. Int J Gynecol Pathol 19:329–334

    Article  PubMed  CAS  Google Scholar 

  383. Spanos WJ Jr et al (1984) Malignant mixed Mullerian tumors of the uterus. Cancer 53:311–316

    Article  PubMed  Google Scholar 

  384. Spiegel GW (1995) Endometrial carcinoma in situ in postmenopausal women. Am J Surg Pathol 19:417–432

    Article  PubMed  CAS  Google Scholar 

  385. Spiegel GW, Austin RM, Gelven PL (1996) Transitional cell carcinoma of the endometrium. Gynecol Oncol 60:325–330

    Article  PubMed  CAS  Google Scholar 

  386. Sreenan JJ, Hart WR (1995) Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am J Surg Pathol 19:666–674

    Article  PubMed  CAS  Google Scholar 

  387. Srodon M, Klein WM, Kurman RJ (2003) CD10 immunostaining does not distinguish endometrial carcinoma invading myometrium from carcinoma involving adenomyosis. Am J Surg Pathol 27:786–789

    Article  PubMed  Google Scholar 

  388. Staebler A et al (2002) Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 26:998–1006

    Article  PubMed  Google Scholar 

  389. Stendahl U et al (1991) Prognostic significance of proliferation in endometrial adenocarcinomas: a multivariate analysis of clinical and flow cytometric variables. Int J Gynecol Pathol 10:271–284

    Article  PubMed  CAS  Google Scholar 

  390. Stewart HJ (1992) The Scottish trial of adjuvant tamoxifen in node-negative breast cancer. Scottish Cancer Trials Breast Group. J Natl Cancer Inst Monogr 11:117–120

    PubMed  Google Scholar 

  391. Susini T et al (1994) Prognostic value of flow cytometric deoxyribonucleic acid index in endometrial carcinoma: comparison with other clinical-pathologic parameters. Am J Obstet Gynecol 170:527–534

    PubMed  CAS  Google Scholar 

  392. Sutton G et al (2000) A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: a Gynecologic Oncology Group Study. Gynecol Oncol 79:147–153

    Article  PubMed  CAS  Google Scholar 

  393. Swerdlow AJ, Jones ME (2005) Tamoxifen treatment for breast cancer and risk of endometrial cancer: a case-control study. J Natl Cancer Inst 97:375–384

    Article  PubMed  CAS  Google Scholar 

  394. Tambouret R, Clement PB, Young RH (2003) Endometrial endometrioid adenocarcinoma with a deceptive pattern of spread to the uterine cervix: a manifestation of stage IIb endometrial carcinoma liable to be misinterpreted as an independent carcinoma or a benign lesion. Am J Surg Pathol 27:1080–1088

    Article  PubMed  Google Scholar 

  395. Tashiro H et al (1997) Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 57:3935–3940

    PubMed  CAS  Google Scholar 

  396. Tashiro H et al (1997) p53 gene mutations are common in uterine serous carcinoma and occur early in their pathogenesis. Am J Pathol 150:177–185

    PubMed  CAS  Google Scholar 

  397. Taskin M et al (1997) bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 10:728–734

    PubMed  CAS  Google Scholar 

  398. Taylor NP et al (2006) Defective DNA mismatch repair and XRCC2 mutation in uterine carcinosarcomas. Gynecol Oncol 100:107–110

    Article  PubMed  CAS  Google Scholar 

  399. Taylor NP et al (2006) DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis. Mod Pathol 19:1333–1338

    Article  PubMed  CAS  Google Scholar 

  400. Taylor RR et al (1999) An analysis of two versus three grades for endometrial carcinoma. Gynecol Oncol 74:3–6

    Article  PubMed  CAS  Google Scholar 

  401. Tiltman AJ (1980) Mucinous carcinoma of the endometrium. Obstet Gynecol 55:244–247

    PubMed  CAS  Google Scholar 

  402. Tobon H, Watkins GJ (1985) Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol 4:328–335

    Article  PubMed  CAS  Google Scholar 

  403. Tornos C et al (1992) Aggressive stage I grade 1 endometrial carcinoma. Cancer 70:790–798

    Article  PubMed  CAS  Google Scholar 

  404. Trere D et al (1994) Interphase AgNOR quantity and DNA content in endometrial adenocarcinoma. Gynecol Oncol 53:202–207

    Article  PubMed  CAS  Google Scholar 

  405. Tsuda H et al (1997) Prospective study to compare endometrial cytology and transvaginal ultrasonography for identification of endometrial malignancies. Gynecol Oncol 65:383–386

    Article  PubMed  CAS  Google Scholar 

  406. Tunc M et al (1998) Endometrium adenocarcinoma with choriocarcinomatous differentiation: a case report. Eur J Gynaecol Oncol 19:489–491

    PubMed  CAS  Google Scholar 

  407. Turner DA et al (1989) The prognostic significance of peritoneal cytology for stage I endometrial cancer. Obstet Gynecol 74:775–780

    PubMed  CAS  Google Scholar 

  408. Ulbright TM, Roth LM (1985) Metastatic and independent cancers of the endometrium and ovary: a clinicopathologic study of 34 cases. Hum Pathol 16:28–34

    Article  PubMed  CAS  Google Scholar 

  409. Vaidya AP et al (2006) Uterine malignant mixed mullerian tumors should not be included in studies of endometrial carcinoma. Gynecol Oncol 103:684–687

    Article  PubMed  CAS  Google Scholar 

  410. van der Putten HW et al (1989) Prognostic value of quantitative pathologic features and DNA content in individual patients with stage I endometrial adenocarcinoma. Cancer 63:1378–1387

    Article  PubMed  Google Scholar 

  411. van Leeuwen FE et al (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448–452

    Article  PubMed  Google Scholar 

  412. van Rijswijk RE et al (1994) The effect of chemotherapy on the different components of advanced carcinosarcomas (malignant mixed mesodermal tumors) of the female genital tract. Int J Gynecol Cancer 4:52–60

    Article  PubMed  Google Scholar 

  413. Vang R et al (2001) Immunohistochemical analysis of clear cell carcinoma of the gynecologic tract. Int J Gynecol Pathol 20:252–259

    Article  PubMed  CAS  Google Scholar 

  414. Vasen HF et al (2004) Identification of HNPCC by molecular analysis of colorectal and endometrial tumors. Dis Markers 20:207–213

    PubMed  CAS  Google Scholar 

  415. Voskuil DW et al (2007) Physical activity and endometrial cancer risk, a systematic review of current evidence. Cancer Epidemiol Biomarkers Prev 16:639–648

    Article  PubMed  Google Scholar 

  416. Wagatsuma S et al (1998) Tumor angiogenesis, hepatocyte growth factor, and c-Met expression in endometrial carcinoma. Cancer 82:520–530

    Article  PubMed  CAS  Google Scholar 

  417. Walker AN, Mills SE (1982) Serous papillary carcinoma of the endometrium. A clinicopathologic study of 11 cases. Diagn Gynecol Obstet 4:261–267

    PubMed  CAS  Google Scholar 

  418. Wang NPSZ et al (1995) Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem 3:99–107

    Google Scholar 

  419. Wani Y et al (2008) Aberrant Cdx2 expression in endometrial lesions with squamous differentiation: important role of Cdx2 in squamous morula formation. Hum Pathol 39:1072–1079

    Article  PubMed  CAS  Google Scholar 

  420. Baergen RN et al (2001) Early uterine serous carcinoma: Clonal origin of extra uterine disease. Int J Gynecol Pathol 20:214–219

    Google Scholar 

  421. Webb GA, Lagios MD (1987) Clear cell carcinoma of the endometrium. Am J Obstet Gynecol 156:1486–1491

    PubMed  CAS  Google Scholar 

  422. Weir HK, Sloan M, Kreiger N (1994) The relationship between cigarette smoking and the risk of endometrial neoplasms. Int J Epidemiol 23:261–266

    Article  PubMed  CAS  Google Scholar 

  423. Wheeler DT et al (2000) Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 24:797–806

    Article  PubMed  CAS  Google Scholar 

  424. Wheeler DT, Bristow RE, Kurman RJ (2007) Histologic alterations in endometrial hyperplasia and well-differentiated carcinoma treated with progestins. Am J Surg Pathol 31:988–998

    Article  PubMed  Google Scholar 

  425. Wheelock JB et al (1985) Uterine sarcoma: analysis of prognostic variables in 71 cases. Am J Obstet Gynecol 151:1016–1022

    PubMed  CAS  Google Scholar 

  426. Witkiewicz AK, McConnell T, Potoczek M, Emmons RUB, Kurman RJ (2010) Increased natural killer cells and decreased regulatory T cells are seen in complex atypical hyperplasia and well-differentiated carcinoma treated with progestins. Hum Pathol 41:26–32

    Article  PubMed  CAS  Google Scholar 

  427. Wolfson AH et al (2007) A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol 107:177–185

    Article  PubMed  CAS  Google Scholar 

  428. Wolfson AH et al (1992) The prognostic significance of surgical staging for carcinoma of the endometrium. Gynecol Oncol 45:142–146

    Article  PubMed  CAS  Google Scholar 

  429. Yamada SD et al (2000) Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer 88:2782–2786

    Article  PubMed  CAS  Google Scholar 

  430. Yamauchi N et al (1996) Immunohistochemical analysis of endometrial adenocarcinoma for bcl-2 and p53 in relation to expression of sex steroid receptor and proliferative activity. Int J Gynecol Pathol 15:202–208

    Article  PubMed  CAS  Google Scholar 

  431. Yamazawa K et al (2000) Prognostic factors in young women with endometrial carcinoma: a report of 20 cases and review of literature. Int J Gynecol Cancer 10:212–222

    Article  PubMed  Google Scholar 

  432. Yazigi R, Piver MS, Blumenson L (1983) Malignant peritoneal cytology as prognostic indicator in stage I endometrial cancer. Obstet Gynecol 62:359–362

    Article  PubMed  CAS  Google Scholar 

  433. Yemelyanova A et al (2009) Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol 33:1504–1514

    Google Scholar 

  434. Yemelyanova A et al (2009) Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol 33:914–924

    Article  PubMed  Google Scholar 

  435. Yokoyama Y et al (2000) Expression of PTEN and PTEN pseudogene in endometrial carcinoma. Int J Mol Med 6:47–50

    PubMed  CAS  Google Scholar 

  436. Young RH, Scully RE (1992) Uterine carcinomas simulating microglandular hyperplasia. A report of six cases. Am J Surg Pathol 16:1092–1097

    Article  PubMed  CAS  Google Scholar 

  437. Zaino RJ (2009) FIGO staging of endometrial adenocarcinoma: a critical review and proposal. Int J Gynecol Pathol 28:1–9

    Article  PubMed  Google Scholar 

  438. Zaino RJ (1995) Pathologic indicators of prognosis in endometrial adenocarcinoma. Selected aspects emphasizing the GOG experience. Gynecologic Oncology Group. Pathol Ann 30(Pt 1):1–28

    Google Scholar 

  439. Zaino RJ et al (1998) DNA content is an independent prognostic indicator in endometrial adenocarcinoma. A Gynecologic Oncology Group study. Int J Gynecol Pathol 17:312–319

    Article  PubMed  CAS  Google Scholar 

  440. Zaino RJ et al (1991) The significance of squamous differentiation in endometrial carcinoma. Data from a Gynecologic Oncology Group study. Cancer 68:2293–2302

    Article  PubMed  CAS  Google Scholar 

  441. Zaino RJ, Kurman RJ (1988) Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma. Semin Diagn Pathol 5:154–171

    PubMed  CAS  Google Scholar 

  442. Zaino RJ et al (1998) Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a gynecologic oncology group study. Am J Surg Pathol 22:1379–1385

    Article  PubMed  CAS  Google Scholar 

  443. Zaino RJ et al (1996) Pathologic models to predict outcome for women with endometrial adenocarcinoma: the importance of the distinction between surgical stage and clinical stage – a Gynecologic Oncology Group study. Cancer 77:1115–1121

    Article  PubMed  CAS  Google Scholar 

  444. Zaino RJ et al (1995) The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer 75:81–86

    Article  PubMed  CAS  Google Scholar 

  445. Zaloudek C et al (1997) Microglandular adenocarcinoma of the endometrium: a form of mucinous adenocarcinoma that may be confused with microglandular hyperplasia of the cervix. Int J Gynecol Pathol 16:52–59

    Article  PubMed  CAS  Google Scholar 

  446. Zelmanowicz A et al (1998) Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 69:253–257

    Article  PubMed  CAS  Google Scholar 

  447. Zheng W et al (1996) p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. Gynecol Oncol 61:167–174

    Article  PubMed  CAS  Google Scholar 

  448. Zheng W et al (1998) p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 22:1463–1473

    Article  PubMed  CAS  Google Scholar 

  449. Ziel HK, Finkle WD (1975) Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167–1170

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, 525 East 68th Street, Starr 1015, New York, NY, 10065, USA

    Lora Hedrick Ellenson

  2. Department of Pathology, Division of Gynecologic Pathology, Johns Hopkins University School of Medicine, Weinberg Building 2242, 401 N. Broadway, Baltimore, MD, 21231, USA

    Brigitte M. Ronnett

  3. Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA

    Robert A. Soslow

  4. Department of Pathology, H179, M.S. Hershey Medical Center, 500 University Drive, Hershey, PA, 17033–0850, USA

    Richard J. Zaino

  5. Departments of Gynecology, Obstetrics, Pathology and Oncology, Division of Gynecologic Pathology, Johns Hopkins University School of Medicine, Weinberg Building Room 2242 401 N. Broadway, Baltimore, MD, 21231, USA

    Robert J. Kurman

Authors
  1. Lora Hedrick Ellenson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brigitte M. Ronnett
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Robert A. Soslow
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard J. Zaino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Robert J. Kurman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lora Hedrick Ellenson .

Editor information

Editors and Affiliations

  1. Departments of Gynecology, Obstetrics, Pathology and Oncology, The Johns Hopkins University School of Medicine and Director of Gynecologic Pathology, The Johns Hopkins Hospital, 401 N. Broadway, Weinberg Building Room 2242, Baltimore, MD, 21231, USA

    Robert J. Kurman (Richard W. TeLinde Distinguished Professor of Gynecologic Pathology) (Richard W. TeLinde Distinguished Professor of Gynecologic Pathology)

  2. Department of Pathology and Laboratory Medicine, Weill Cornell Medical College and New York Presbyterian Hospital, 525 East 68th Street, Starr 1015, New York, NY, 10065, USA

    Lora Hedrick Ellenson

  3. Department of Pathology, Johns Hopkins University School of Medicine, 401 N. Broadway, Weinberg Building 2242, Baltimore, MD, 21231, USA

    Brigitte M. Ronnett

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this entry

Cite this entry

Ellenson, L.H., Ronnett, B.M., Soslow, R.A., Zaino, R.J., Kurman, R.J. (2011). Endometrial Carcinoma. In: Kurman, R.J., Ellenson, L.H., Ronnett, B.M. (eds) Blaustein’s Pathology of the Female Genital Tract. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0489-8_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0489-8_9

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4419-0488-1

  • Online ISBN: 978-1-4419-0489-8

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation